Drug Profile
Research programme: cancer immunotherapeutics - AbeXXa Biologics/Boehringer Ingelheim
Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator AbeXXa Biologics; Boehringer Ingelheim
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action HLA antigen modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer